capital) nor coastal regions. 1 The aim of this study was to assess the genetic diversity and prevalence of drug-resistant mutations among HIV-infected pregnant women.
METHODS

Ethical considerations and study population
The 
Gene sequencing
Viral RNA was extracted by using the QIAamp Viral RNA minikit (QIAGEN, Germany), with reverse transcription into cDNA (RT-PCR) and polymerase chain reaction (PCR) amplification using both "in-house" methodology and the Trugene commercial system (Trugene HIV-1 genotyping assay, Siemens Diagnostics, USA). The entire protease (PR) and 75% of the reverse transcriptase (RT) were sequenced in an automatic sequencer. All DNA sequences were analyzed using the OpenGene DNA sequencing system (Trugene, Siemens) and, for the 'in-house' sequencing, the Applied Biosystems ABI3130xl system (Applied Biosystems, USA). Chromatograms were verified using the SeqMan v7 software (LaserGene; DNAStar, USA) and were then compared with HIV-1 reference sequences. The sequences obtained here were submitted to GenBank under the accession numbers MF554758
to MF554780 and MF669076 to MF669087.
Resistance and phylogenetic analysis
To define the HIV-1 genetic subtype, interpretations of DNA sequences were made using both the Brazilian algorithm and the REGA HIV-1 tool, version 3.0. The transmitted drug resistance profile was evaluated using the Stanford HIV resistance database, and presence of transmitted drug resistance was evaluated using A significance level of 5% was used for all statistical tests.
These tests were performed in the SAS software, version 9 (Statistical Analysis System, SAS Institute Inc, USA).
RESULTS
Characteristics of the study population
Eighteen pregnant women (47.4%) were naive, while 20 (52.6%) had already used antiretroviral therapy before the current pregnancy or were using it during the pregnancy (cARVT-exposed). Most of the women enrolled (81.6%) had been diagnosed with HIV infection during prenatal care for the current or a previous pregnancy. numbers of pregnancies and deliveries were higher among the cARVT-exposed women: on average, these women began prenatal care at an earlier gestational stage than did the naive pregnant women (35.0% vs. 21.0% in the first trimester). Most participants (86.8%) were asymptomatic. Viral load distribution was similar between the cARVT-exposed and naive pregnant women (P = 0.65), although with greater variation in the cARVT-exposed women. The median CD4+ T lymphocyte count was greater among the cARVT-exposed pregnant women, and the median CD8+ T lymphocyte count was greater among the naive pregnant women, but there was no statistical difference for either of these parameters between the two groups (P = 0.76 and P = 0.59, respectively).
At the first outpatient visit, it was observed that, among the 20 cARVT-exposed pregnant women, six were undergoing a therapy regimen. In this subgroup, 27.8% had used or were using monotherapy, whereas 15.0% had used a three-drug regimen. The most commonly used drug combination was zidovudine + lamivudine + nelfinavir (50.0%), followed by zidovudine + lamivudine + lopinavir/ritonavir (44.4%), zidovudine + lamivudine + efavirenz (22.2%) and zidovudine + lamivudine + other drugs (11.1%). Because the drug combinations used varied over time, the percentages do not total 100%.
In addition to HIV infection, 38.9% of the naive and 50.0% of the cARVT-exposed pregnant women presented other sexually transmitted infections (STIs), like syphilis, trichomoniasis, Ureaplasma, genital warts or grade I cervical intraepithelial neoplasia. STIs plus genital infection (vaginal candidiasis and bacterial vaginosis) were also observed in 22.2% of the naive pregnant women and in 10.0% of the cARVT-exposed pregnant women. There were no statistically significant differences in viral load or in CD4+ and CD8+ T lymphocyte counts among women with STIs (P = 0.93, P = 0.41 and P = 0.26, respectively) or among those with STIs plus genital infections (P = 0.23, P = 0.14 and P = 0.18, respectively), in comparison with the women who did not have any of these conditions.
Diversity of HIV subtypes
Subtype B was identified in 84.2% of the samples, F1 in 5.3%, recombinant forms B/F and F/B in 7.9% and the unique recombinant form (URF) K/F in 2.6%. Most circulating recombinant forms (CRFs) were composed of subtypes B and F1, and phylogenetic analysis showed that these had a close relationship to CRF29_BF, which was described in the city of São Paulo (SP), Brazil (http:// www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html).
Among the naive pregnant women, 83.4% presented subtype B and 5.6% had subtype F1, while the recombinant forms B/F and K/F were also present in one pregnant woman each. Among the cARVT-exposed pregnant women, subtype B was also the most prevalent, with an incidence of 85.0%, followed by the recombinant form B/F (10.0%) and subtype F1 (5.0%). Subtype F1 sequences comprised a separate cluster, and were identical to sequences from the southeastern region of Brazil.
A cluster among subtype B sequences was observed, suggesting Table 2 . HIV-1 subtypes and resistance mutations associated with analogous nucleoside/nucleotide reverse tran scriptase inhibitors (NRTI), non-analogous nucleoside reverse tran scriptase inhibitors (NNRTI) and protease inhibitors (PI) cARVT = combined antiretroviral therapy; PW = pregnant women; NRTI = nucleoside/nucleotide reverse transcriptase inhibitors; NNRTI = non-analogous nucleoside reverse transcriptase inhibitors.
thymidine inhibitors (TAM) (10.0%). The V75M mutation associated with resistance to didanosine and stavudine was detected in one sample (5.0%). Three samples displayed K103N, E138A and P225H mutations, one per sample. Two samples showed concomitant mutations associated with NRTI and PI (sample 98), and NRTI and NNRTI (sample 110). Two samples had the M46L mutation (10.0%) and one had the I50L mutation (5.0%) associated with atazanavir. Also, the most prevalent accessory mutations were L10I/V and K20M/R (10%), which were detected in two sequences (samples 16 and 115). None of the samples from the cARVT-exposed pregnant women showed resistance to three classes of drugs.
The number of antiretroviral regimens previously used was associated with the presence of drug-resistant viruses (P = 0.041).
The cARVT-exposed pregnant women had 2.10-fold higher No case of mother-to-child transmission of HIV was diagnosed among the pregnant women included in this study.
DISCUSSION
In this study, subtype B was the most common form of HIV-1 Ferreira et al. 22 found that the prevalence of transmitted drug resistance in São Paulo and Campinas was 7.6% and that 76.0% of these cases carried mutations for resistance to NNRTIs.
Among the cARVT-exposed pregnant women, major resistance mutations were present in 35.0%. However, this may have been an overestimation, due to the small sample size in this study. The most frequent mutation was M184V, which caused resistance to lamivudine and intermediate resistance to abacavir and didanosine, along with increased susceptibility to zidovudine, stavudine and tenofovir. Three pregnant women whose HIV-1 strains presented this mutation had already used cARVT containing lamivudine.
Other studies on patients who had already been treated with several antiretroviral regimens also observed higher frequency of the M184V mutation, in up to 88.0% of the individuals evaluated. 14, 17, 24 It was expected to find drug-resistant mutations among women who had had a diagnosis of HIV infection for a longer showed that no major mutations conferring drug resistance were found in the naive pregnant women, but that major mutations were found in 35.0% of the cARVT-exposed pregnant women.
